Search Results - "Ecca, Fabrizio"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk by De Mattia, Elena, Silvestri, Marco, Polesel, Jerry, Ecca, Fabrizio, Mezzalira, Silvia, Scarabel, Lucia, Zhou, Yitian, Roncato, Rossana, Lauschke, Volker M., Calza, Stefano, Spina, Michele, Puglisi, Fabio, Toffoli, Giuseppe, Cecchin, Erika

    Published in Biomedicine & pharmacotherapy (01-10-2022)
    “…Preemptive targeted pharmacogenetic testing of candidate variations in DPYD is currently being used to limit toxicity associated with fluoropyrimidines. The…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation by Cecchin, Erika, De Mattia, Elena, Ecca, Fabrizio, Toffoli, Giuseppe

    Published in Drug resistance updates (01-07-2018)
    “…Adverse events affect the pharmacological treatment of approximately 90% of colorectal cancer (CRC) patients at any stage of the disease. Chemotherapy…”
    Get full text
    Journal Article
  5. 5

    Immunogenetics of prostate cancer: a still unexplored field of study by Dreussi, Eva, Ecca, Fabrizio, Scarabel, Lucia, Gagno, Sara, Toffoli, Giuseppe

    Published in Pharmacogenomics (01-02-2018)
    “…The immune system is a double-edged sword with regard to the prostate cancer (PCa) battle. Immunogenetics, the study of the potential role of immune-related…”
    Get full text
    Journal Article
  6. 6

    Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects by Russo Spena, Concetta, De Stefano, Lucia, Poli, Giulio, Granchi, Carlotta, El Boustani, Maguie, Ecca, Fabrizio, Grassi, Gabriele, Grassi, Mario, Canzonieri, Vincenzo, Giordano, Antonio, Tuccinardi, Tiziano, Caligiuri, Isabella, Rizzolio, Flavio

    Published in Journal of cellular physiology (01-09-2019)
    “…Peptidyl‐prolyl cis–trans isomerase, NIMA‐interacting 1 (PIN1) is a peptidyl‐prolyl isomerase that binds phospho‐Ser/Thr‐Pro motifs in proteins and catalyzes…”
    Get full text
    Journal Article
  7. 7
  8. 8

    The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines by De Mattia, Elena, Roncato, Rossana, Dalle Fratte, Chiara, Ecca, Fabrizio, Toffoli, Giuseppe, Cecchin, Erika

    Published in Cancer drug resistance (01-01-2019)
    “…Fluoropyrimidines (FP) are given in the combination treatment of the advanced disease or as monotherapy in the neo-adjuvant and adjuvant treatment of…”
    Get full text
    Journal Article
  9. 9